Printer Friendly

HLA-G as a tolerogenic molecule in transplantation and pregnancy.

1. Introduction

Both solid organ and hematopoietic stem cell transplantation (HSCT) represent life-saving therapies for patients with end stage organ failure or severe haematological malignancies, respectively. However, genetic incompatibilities between donor and recipient, in particular among classical human leukocyte antigen (HLA) class I (HLA-A, -B, -C) and class II (HLA-DR, -DQ, -DP) molecules, lead to a powerful alloresponse by the adaptive and/or innate immune system, which has to be controlled by immunosuppressive drugs. Despite the development of modern immunosuppressive strategies, the induction of such reactions cannot always be completely prevented, and acute or chronic rejection remains a major complication in transplantation. Another set of problems in transplantation arose due to the toxicity of immunosuppressive drugs. Thus, the success of transplantation depends on the balance between rejection and the side effects of modern immune suppressants.

The development of a certain degree of immune tolerance against allogeneic antigens can favour a successful outcome. In solid organ transplantation the induction of tolerance can diminish the risk of acute and chronic graft rejection and thereby improve the survival of the allograft. In HSCT tolerance may weaken host versus graft (HvG) as well as graft versus host disease (GvHD). Experimental research on naturally occurring mediators for immune tolerance represents one approach to design new strategies providing a more effective therapy of transplanted recipients.

Decades of research have identified HLA-G as a naturally occurring tolerance-inducing molecule. This molecule is operative in pregnancy, which is the only true physiological situation of tolerance towards a semiallograft. HLA-G belongs to nonclassical HLA class I family. Although it shares some structural similarities with classical HLA class I, several important differences render HLA-G unique among HLA class I molecules: it displays a low allelic variation, a restricted peptide repertoire [1-3], an unusually high diversity of molecular structures due to alternative splicing of the primary transcript [4-6], and a restricted expression under physiological conditions, which can be upregulated in various situations. HLA-G has originally been discovered on the extravillous cytotrophoblast at the maternal-fetal interface [7]. It is also expressed by amnion epithelial cells [8, 9], erythroid, and endothelial cells of fetal blood vessels in the placenta [10, 11], as well as in the thymus [12], cornea [13], pancreas [14], and nail matrix [15]. Although marginal, the levels of HLA-G specific transcripts are found in nearly all tissues analysed, for example, fetal liver, myelomonocytic cells, fetal and adult eye tissue, skin and keratinocytes, and peripheral blood lymphocytes [16]. The latter can release substantial amounts of soluble HLA-G (sHLA-G) into the blood circulation [17-19].

The initial discovery of HLA-G on the extravillous cytotrophoblast soon led to the concept that it is involved in mechanisms of tolerance. Today, it is seems that an enhanced HLA-G expression in transplants or in the circulation of its recipient is associated with the acceptance of allogeneic graft, but only a minority of patients express high levels of this molecule. In this contribution we focus on (i) how HLA-G is involved in human reproduction and transplantation, (ii) how HLA-G is regulated by genetic and micro-environmental factors, and (iii) how HLA-G offers novel therapeutic options in transplantation.

2. The Structural Basis for the Recognition of HLA-G by Immune Receptors

Seven different isoforms derived from alternative splicing of the primary transcript are known. Four of them are membrane-anchored molecules (HLA-G1, -G2, -G3, and -G4) and the remaining three isoforms (HLA-G5, -G6, and -G7) represent secreted molecules as the transmembrane region is missing [4-6]. The HLA-G1 and HLA-G5 molecules represent the full extracellular length composed of three alpha domains assembled with [beta]2-microglobulin ([beta]2m) in the endoplasmatic reticulum. Variants of these molecules can also exist in non-[beta]2m-associated structures [20, 21]. The structures associated with [beta]2m present nonameric peptides [2]. However, the peptide repertoire is restricted compared to classical HLA molecules, as all amino acid exchanges of HLAG occur outside the peptide-binding groove of the alpha 1- and alpha 2-domain [22]. Consequently HLA-G is not recognized as a foreign antigen by the T cell receptor and therefore does not induce a T cell based immune response, which is the main functional arm in transplantation. The other non-[beta]2m associated structures are truncated isoforms missing one or two [alpha]-domains. All full-length isoforms [23, 24] as well as all other truncated ones [25] are able to form disulphide-linked dimers due to the cysteine residue at position 42. All membrane-anchored molecules can further be released into circulation either as shed molecules [17] or via microvesicles (MV) such as exosomes [26, 27].

Regarding function, HLA-G preferentially acts as ligand for two inhibitory receptors including the immunoglobulin-like transcript (ILT) receptor-2 (LILRB1/CD85j) and ILT4 (LILRB2/CD85d). Both receptors recognize the alpha-3 domain of HLA-G, but these two receptors distinguish different structures of HLA-G: the ILT2 receptor interacts with [beta]2m-associated HLA-G molecules, whereas the ILT4 receptor recognizes non-[beta]2m-associated structures. ILT2/4 receptors are expressed on subpopulations of T, B, and NK cells and on monocytes/macrophages/dendritic cells [28-33]. Due to the functionality of these receptors and their expression profile, HLA-G has the capability to modulate the immune response of the adaptive and/or of the innate immune system. As sHLA-G and membrane-anchored structures exhibit the same receptor specificity, both HLA-G and its soluble counterparts are potent molecules modulating the innate and adaptive immune response. However, dimers of HLA-G/sHLA-G bind to these receptors with a superior avidity than HLA-G/sHLA-G monomers or classical HLA class I molecules do [24, 34]. This emerges the question whether the generation and/or the quantity of dimers may regulate the signaling potential of these ILT receptors. Receptor binding assays, enabling to define the amount of dimers as recently introduced [35], may give further lights into this problem.

HLA-G is also reported to be ligand for the killer immunoglobulin-like receptor 2DL4 (KIR2DL4/CD158d), which is expressed on NK cells [36]. Remarkably this receptor is mainly expressed on decidual NK cells, suggesting a delicate role in pregnancy [29]. At variance to ILT2/4, the monomeric/dimeric status of HLA-G has no impact on the binding avidity towards this receptor [23,24, 34]. Even more, the functional outcome of HLA-G/KIR2DL4 engagement is not easily predictable in an in vivo situation, as KIR2DL4 bears two elements, the one for inhibition in its cytoplasmic tail and the other one for activation in the transmembrane region. Furthermore, controversial information about the surface expression of 2DL4 on NK cells and its exclusively and specific binding to HLA-G as well as the resulting functional consequence are available: in early studies the surface expression of this receptor on peripheral blood cells was found to be expressed in every human NK cell clone tested and in all human subjects [29], whereas later studies demonstrated that KIR2DL4 expression depends on certain KIR2DL4 alleles [37] and is normally restricted to a CD56high subset of NK cells [38] even if KIR2DL4 is constitutively expressed on a transcriptional level in all NK cells [39]. Clearly, KIR2DL4-immunoglobulin fusion protein is able to interact with surface expressed HLA-G or soluble forms [29, 40, 41]. Here it is reported that residues Met76 and Gln79 specific for HLA-G are involved in KIR2DL4 recognition [36]. As 2DL4 is found to be present in endosomes of resting NK cells colocalized with sHLA-G, it was suggested that sHLA-G molecules were internalized after binding to 2DL4 [41]. Functionally, KIR2DL4 is reported to trigger a potent proinflammatory production of cytokines, chemokines, and angiogenic factors but only weak cytotoxicity in resting NK cells [38, 41, 42]. Whether the functional consequences are exclusively attributed to the interaction of KIR2DL4 to HLAG is a matter of debate as the first results on this topic were partly corrected by the authors themselves as followed: the expression system in the cell line NK-92 that was used to test functional recognition of HLA-G by KIR2DL4 had been unreliable as the NK-92 cell line infected with recombinant vaccinia viruses that do not encode KIR2DL4 showed the same results. Recently, it was figured out that the IFN-[gamma] response of freshly isolated NK cells towards soluble HLAG preparations was found to be absolutely dependent on the presence of small numbers of contaminating myeloid dendritic cells. This leads to the question whether the detected cytokine response mentioned in other studies might be due to improper NK cell isolation and due to the availability of other cell populations bearing HLA-G specific receptors such as myeloid dendritic cells [43]. Moreover, KIR2DL4 can interact with alternative ligand(s) expressed by cells of epithelial or fibroblast origin. Importantly, KIR2DL4 recognition of cellular ligands is directly regulated by heparan sulfate glucosamine 3-O-sulfotransferase 3B1 [44]. Thus, studies on the interaction of cell-surfaced expressed KIR2DL4 and HLAG should be critical reevaluated with regard to the receptor specificity and the presence of heparan sulfate glucosamine 3-O-sulfotransferase 3B1.

Similar to classical HLA class I molecules the full extracellular length HLA-G structures (HLA-G1 and HLA-G5) are able to interact with the CD8 coreceptor on T and on subpopulations of NK cells. Here the affinity to CD8 does not differ between HLA-G and classical HLA class I molecules [45]. Notably, the engagement of sHLA-G1/G5 with CD8 results in the induction of Fas/FasL-mediated apoptosis in CD8 bearing cells and in the inhibition of cytotoxic T cell activity [46-48].

Furthermore, HLA-G molecules can indirectly interact with the activators CD94/NKG2C and inhibitory CD94/ NKG2A receptor/ligand system. Here, a nonameric peptide derived from leader sequence of HLA-G seems to increase and stabilize HLA-E, another member of the nonclassical HLA class I family at the cell surface [49]. These receptor systems are expressed on NK cells and on certain subpopulations of other effector cells [29, 50].

3. How Can HLA-G Shape the Immune System towards Tolerance in Transplantation and Pregnancy?

In transplantation and pregnancy, tolerance can be achieved by processes of deletion of reactive cells, by induction of anergy, and by other immune regulating mechanisms like the induction of regulatory/suppressor cells. Regulatory cells may exist in various cell subpopulations including antigen presenting cells (APC), CD8 T cells, and CD4 T cells.

In vitro experiments have shown (Figure 1) that HLAG/sHLA-G molecules derived from transplanted patients or from isolated cultured cytotrophoblast cells initiate a short-term inhibitory effect on T cells, NK cells, and B cells by binding with ILT2, ILT4, and KIR2DL4 [51-54]. In consequence, HLA-G inhibits the activity of CD8 positive cytotoxic T cells, peripheral and decidual NK cells [46, 48, 55-57], the allogeneic proliferation response of CD4 positive T cells [58] and cell cycle progression of alloreactive T cells [59, 60]. In all experimental settings the inhibitory effect of HLA-G could be abolished in the presence of a blocking antibody specific for HLA-G. Interestingly, the binding of HLA-G with ILT2 suppresses both, the naive and the memory B cell functions. In particular HLA-G is able to impede B cell proliferation, differentiation, and Ig secretion in both T cell-dependent and -independent models of B cell activation. Furthermore, it seems that HLA-G acts as a negative B cell regulator in modulating B cell antibody secretion in a xenograft mouse model [61].

An indirect inhibitory effect of HLA-G is that its presence leads to an enhanced expression of ILT2, ILT3, ILT4, and KIR2DL4 receptors in antigen-presenting cells, NK cells, and T cells. This upregulation seems not to require any antigenic costimulation. It is discussed that by the upregulation of inhibitory receptors the threshold level for an immune activation is increased in effector cells of recipients, which in turn may result in a better graft acceptance [53]. A further important indirect way, how HLA-G exerts inhibition of effector function, is the induction of HLA-E on cell surface expression by providing HLA-G specific leader peptides. The interaction of HLA-G leader peptides with the inhibitory receptor complex CD94/NKG2A results in prevention of NK cell-dependent lysis. Lastly, HLA-G-expressing cells modulate the ability of decidual mononuclear cells or peripheral blood mononuclear cells to release cytokines in a way that may shift the Th1/Th2 balance towards relative Th2 dominance [62]. In addition, the presence of sHLA-G molecules stimulates especially the release of IL-10 [63].

In addition to these short term effects (Figure 1), HLA-G can also provide long term inhibitory effects by the induction of regulatory or suppressor cells [52] that should contribute to the development of tolerance. The interaction of HLA-G with the ILT4 receptor can initiate such long term effects. In a mouse transplant model [64, 65] it has been shown that the engagement of ILT4 with HLA-G5 dimer or HLA-G1 tetrameric complex on antigen presenting cells (APC), such as dendritic cells (DC), inhibits their maturation resulting in anergy and in a diminished MHC class II, CD80, and CD86 expression. These anergic DCs have the capability to favour the differentiation of regulatory T cells and to prolong significantly allograft survival. In addition there is first evidence that myeloid cells are also sensitive to HLA-G, as they have ILT2 and ILT4 receptors expressed on cell surface. In ILT2 transgenic mouse model it could be demonstrated that HLA-G induces the differentiation of myeloid derived suppressor cells that promote long term graft survival [66].

An indirect inhibitory effect of HLA-G, which induces long term tolerance, has been shown for CD4+T cells and CD8+T cells stimulated by HLA-Gl-expressing APC [67]. These T cells lose their capability to response to stimulation and differentiate into regulatory T cells. Once generated, the tolerance-inducing functions of these cells are independent from HLA-G. HLA-G-expressing APC can be generated in vitro by the differentiation of monocytes into DC in the presence ofinterleukin-10 (IL-10) [68]. These so-called DC-10 are tolerogenic DCs and characterized by the high expression intensities of HLA-G1, ILT2, ILT4, and ILT3 and their production of high IL-10 levels. Functionally, DC-10 is able to induce adaptive allospecific regulatory T cells (Tr1) through the IL10-dependent ILT4/HLA-G pathway. Tr1 cells are known to exert immune suppression by producing high levels of IL10 in the absence of IL-4 [68, 69]. Such DC-10 can also be found in vivo in peripheral blood as well as in secondary lymphoid organs. In the pregnancy microenvironment, the maintenance of tolerance during the first trimester may be one of the major roles of this APC subset. The human decidua presents higher frequency of tolerogenic DC-10 if compared with peripheral blood of pregnant women. This observation can be attributed either (i) to the recruitment of DC-10 from peripheral blood or (ii) to the conversion of resident decidual DCs into DC-10 or lastly (iii) to de novo induction of DC-10 by the IL-10 dependent ILT4/HLA-G pathway [70].

4. How Is HLA-G Expressed in the Normal or Pathological Course of Pregnancy or Transplantation?

Most of the functional implications of HLA-G in tolerance have been established in in vitro models. However, studies on HLA-G expression in allogeneic situations such as pregnancy and transplantation and its association to the clinical course further support the crucial role of HLA-G in mediating or maintaining tolerance in vivo.

5. HLA-G Expression in Pregnancy

HLA-G specific transcripts are detectable in oocytes as well during implantation development: The frequencies of embryos expressing the full extracellular length isoforms HLA-G1/G5 increase with ascending developmental and cleavage stages [71, 72], and the presence of HLA-G transcripts in blastocysts is associated with higher cleavage rate and a higher pregnancy rate [73, 74]. Several single and multicentre studies (for review see [75-77]) have firmly demonstrated that sHLA-G molecules can be found in embryo cultures (EC) after human-assisted reproduction techniques (ART). In concordance to the mRNA expression profile the proportion of sHLA-G positive EC increases with the developmental stages of the embryo [78], indicating that besides the morphological scoring system of embryos the detection of sHLA-G in EC represents an additional parameter for the prediction of pregnancy outcome after ART. With regard to HLA-G structures there are two studies demonstrating that only half of HLA-G-expressing blastocysts coexpressed the [beta]2-m transcripts [73, 74]. This indicates that these blastocysts have the prerequisite available to form functional active [beta]2m-associated HLA-G1 dimers known to interact with ILT2, whereas the other HLA-G-expressing blastocyst should at least be qualified to form non-[beta]2m-associated structures interacting with the ILT4 receptor. Interestingly, the alternatively spliced transcripts HLA-G3 and HLA-G4 isoforms are the most abundant ones during implantation development [71]. This observation raises questions about the functional relevance and possible novel unknown HLA-G receptors for HLA-G3/4 operative in pregnancy, which may also be relevant in transplantation.

The arrival of the blastocyst in the uterine cavity promotes functional and molecular immune modulatory changes in endometrial cells and in the blastocyst itself, resulting in adhesion, trophoblastic invasion, decidualization, and placentation [76]. Taking into account all the mechanisms leading to a successful embryo implantation, the unusual phenotype of the semiallogeneic extravillous trophoblastic cells (ETC) seems to have the most prominent influence on the induction of feto-maternal tolerance. The ETC preferentially express HLA-G (for overview see [75,76]) as well as low levels of HLA-E and HLA-F [79], a third nonclassical HLA molecules, but do not express classical HLA class I (HLA-A and -B) and HLA class II (HLA-DR, -DQ and -DP). HLA-G is recognized to be a key molecule in embryo implantation, modulating the local immune response by mechanisms mentioned before, which in sum results in the suppression of the maternal immune system (for overview see [75, 80, 81]). In normal pregnancy the membrane-bound HLA-G1 and the secreted HLA-G5 isoforms are the most abundant HLA-G molecules during invasions. Interestingly, different structures are found in certain trophoblast subpopulations: At the leading edge of trophoblast columns and on invading ETC HLA-G1 isoform is expressed as [beta]2-associated homodimer [82]. The HLA-G5 isoform is ubiquitously expressed in all types of trophoblast populations either in a [beta]2-associated structure on ETC or in a non-[beta]2m-associated dimeric structure on villous trophoblasts [83]. HLA-G5 produced locally by ETC is discussed to alter the maternal cytokines profile in a normal successful pregnancy. Recently, a multicenter study has provided substantial evidence [84] that the HLAG5 can induce the IL-4 production by decidual CD4+T cells via ILT2 receptor expression on decidual T cells. Here, ILT2 seems to be upregulated on the activated CD4+T cells and downregulated in activated macrophages. The increased number of ILT2 receptors on the CD4+T cell surfaces enhances the binding efficiency of the HLA-G5 molecule and consequently the secretion of IL-4, which appears to be one of the critical anti-inflammatory interleukins for successful pregnancy.

Interestingly, CD4 or CD8 positive T cells expressing constitutively HLA-G can also be found in the peripheral blood and in the decidua during pregnancy [70]. These cells are described to exert T regulatory (Treg) functions in vitro like the potent suppression of T cell proliferation. Originally, these kinds of Treg cells have been discovered to be accumulated at site of inflammation 85].

Recurrent spontaneous abortion (RSA) and preeclampsia have been discussed to be caused by an insufficient immune tolerance at the maternal-fetal interface. Considering the functionality of HLA-G, the low HLA-G expression in placental tissue obtained from women experienced pregnancy complications supports these discussions [86-89].

During the course of an uncomplicated pregnancy altering sHLA-G levels are observed in the peripheral blood of the mother's levels: in the first gestational trimester the sHLAG levels increase until reaching the highest peak at month three of gestation [90, 91] and start to decrease again during the third trimester [92]. Undetectable sHLA-G or variation in the course of sHLA-G especially during in the first weeks of gestation seems to be related with gestational complications, implantation failure, miscarriage and spontaneous abortion, preeclampsia, and placental rupture (for a concise review see [75, 76]). It has been reported that sHLA-G molecules contribute to modulation of maternal cytokine profile, in particular the upregulation of anti-inflammatory cytokines such as IL-3, IL-4, and IL-10 [93].

6. HLA-G and Transplantation

The first evidence that HLA-G expression is involved in transplantation has been reported for heart transplantations [94]. In 36 noninflammatory heart transplant recipients, the expression of HLA-G in endomyocardial biopsies or in serum samples of patients had clearly been associated with a decrease of acute and chronic cellular rejection episodes [94]. These results have been confirmed by other studies indicating that HLA-G or sHLA-G molecules contribute to an improved heart allograft acceptance after transplantation [95, 96]. Regarding sHLA-G, both the basal levels in pretransplant patients and its alteration after heart transplantation seem to be useful to monitor the development of transplantation. Interestingly, a recent study provides first hints that in patients with a biopsy proven humoral rejections the circulating sHLA-G levels are reduced compared to patients without any sign of rejections [97]. Here, it is very likely that sHLA-G is involved in the modulating B cell functions in vivo, as recently evidenced by in vitro experiments [61]. Regarding the source of sHLA-G, one in vitro study gives hints that during an allogeneic reaction HLA-G5 is released by allospecific CD4(+) T cells, resulting in the suppression of the proliferative T cell response [98]. Controversial results have been reported for cardiac allograft vasculopathy (CAV), which is a major limitation of long-term survival after heart transplantation: in one study sHLA-G levels have been found to be increased in recipients without heart allograft CAV compared to recipients suffering from severe CAV post transplantation [99], whereas the another one could not observe any differences between these two patients groups [100].

In lung, liver, kidney, combined liver-kidney, or combined kidney-pancreas transplantation there is an overall concurrence that increased HLA-G expression in biopsies [101-103] or high circulating sHLA-G levels [102, 104-108] has always been associated with a better graft acceptance in terms of acute and chronic cellular rejections. Of note, in kidney transplant patients, there is an inverse association of sHLA-G with organ failure from chronic rejection and with the production of anti-HLA IgG antibodies. This is the second evidence that HLA-G contributes to the modulation of B cell functions in vivo, which in turn might prevent a humoral rejection. In kidney, liver, or combined liver-kidney transplantation, enhanced sHLA-G levels are concomitantly with high IL-10 levels and novel CD3+CD8low and CD3+CD4low suppressor T cells being negative for FOXP3, a common marker for regulatory T cells. In vitro experiments (Figure 1) have shown that these two types of regulatory T cells can be induced by HLA-G-expressing APC or HLA-G5 molecules [104].

Several studies have analysed the putative role of HLAG/sHLA-G expression in the allogeneic hematopoietic cell transplantation setting. Indeed, increased HLA-G5 levels on day 15 and on day 30 after HCST seem to be negatively correlated with the severity of aGvHD [109] suggesting HLAG5 as a predictor of the occurrence and severity of aGvHD. This concept has been further sustained by the fact that high levels of HLA-G before and after allograft are indicative for good HCST outcome with respect to the occurrence of aGvHD. The involvement of sHLA-G molecules in aGvHD prevention is further supported by the positive correlation of sHLA-G levels with the number of regulatory T cells [110]. Nevertheless, in the study of Waterhouse et al. [111] certain sHLA-G levels could not be related to aGvHD, disease recurrence, or death implying a weak or negligible involvement of sHLA-G in the outcome of HCST.

7. The Impact of the Genetic Background on HLA-G Expression in Pregnancy and Transplantation

In general, HLA-G presents low polymorphisms as compared to classical HLA class-I antigens. The IMGT/HLA Database (http://hla.alleles.org/, version 3.14.0, October 2013) contains fifty HLA-G alleles resulting in 16 different proteins (HLAG*0101, *0102, *0103, *0104, *0106, *0107, *0108, *0109, *0110, *0111, *0112, *0114, *0115, *0116, *0117, and *0118) and 2 null alleles. The variations in the amino acid sequence between the allelic variants of HLA-G are located in coding and in non-coding regions, which may affect the biological properties of HLA-G.

In the coding region, 18 out of 50 HLA-G alleles determine four membrane-bound (HLA-G1, HLA-G2, HLA-G3, and HLA-G4) and three soluble forms of HLA-G (HLA-G5, HLA-G6, and HLA-G7) produced by alternative splicing. The exceptions are represented by currently two described null alleles (HLA-G*01:05N and HLA-G*01:13N), which lead to the generation of a reduced number of HLA-G isoforms or to the lack of a functional protein. The HLA-G*01:05N allele is the result of a deletion at position 130 in exon 3 leading to a shift in the open reading frame and the generating of a stop codon (TGA) at position 189 in exon 4 [112]. In consequence, the synthesis of the a2 domain is prevented. The exclusive synthesis of HLA-G2, -G3, and -G7 isoforms remains to imply an immune relevant property of this structural variants [113]. In HLA-G*01:13N a single exchange of cytosine to thymidine at position 54 results in a stop codon (TAG) in exon 2 and in the absence of a HLA-G protein [114]. The frequency of HLA-G*01:05N is higher than 10% in African and Indian populations [115,116], whereas the null allele HLA-G*01:13N is rare and has only been described in the African population [114].

Four variable amino acid positions are present in the a1 domain (codon 13, 27, 31, and 54), six variations in the a2 domain (100, 104, 105, 110, 130, 159, and 169), and four in the a3 domain (185, 189, 219, and 258) [117-119]. These variations may lead to altered protein conformation of HLAG, which could result in different biological functions, for example, affinity to receptors. Three different alleles have been described to vary in the intron 2, 3 and 5 regions [120-122]. The underlying importance and mechanism are unknown, yet.

Due to the tolerance-mediating role of HLA-G great efforts have been made to identify genetic factors influencing the HLA-G expression to predict its presence in allogeneic situations and thereby to estimate the development of naturally occurring immune tolerance.

The concept that HLA-G expression is under genetic control has been introduced by the observation that the amounts of circulating sHLA-G molecules are associated to certain HLA-G alleles [123]. In this study high levels could be related to the HLA-G* 01:04:01, whereas reduced sHLA-G levels has been associated with the alleles HLAG*01:01:03 and G*01:05N. Whereas HLA-G*01:04:01 and HLA-G*01:01:03 represent synonymous nucleotide variations in the coding region compared to the most common allele HLA-G*01:01:01, the HLA-G*01:05N is defined by the loss of HLA-G1 expression as well as its soluble counterpart HLAG5 as already mentioned. Interestingly, these alleles are often reported to be associated in unexplained recurrent abortion [116, 123-125]. In addition, these HLA-G alleles could be related to a higher rejections probability in renal transplant patients [126].

The noncoding region of the HLA-G gene consists of the promoter region and the 3,UTR region, which are important for the regulation of gene expression and mRNA stability. The majority of polymorphic sites is located in the promoter 5' upstream regulatory (57URR) and 3' untranslated (3'UTR) regions have been reported to influence HLA-G expression [127,128]. Regarding to the 57URR promoter region [129,130], the unusual feature of the cis-acting regulatory elements, such as the modified enhancer A (enhA) and a deleted interferon-stimulated response element (ISRE), modifies its binding properties and determine its responsiveness to nuclear factor-kappa B (NF-[kappa]B) and interferon-[gamma] (IFN-[gamma]), which in turn can influence the protein expression of HLA-G. To date 29 SNP positions have been identified, all of which flank promoter elements [131,132]. Clinically relevant polymorphisms in the 57URR are scarce: the A/C sNp at position -486 and the 725G allele have been found to be associated with miscarriage [133, 134]. The presence of a guanine at position -725 creates a CpG dinucleotide between -725 and -726 nucleotides, which can be methylated on -725G variants. This epigenetic variance may influence the binding site for the transcription factor IRF-1 (interferon regulatory factor-1) and interfere in HLA-G transcription and consequently in HLA-G expression [133]. Furthermore, SNPs at positions -964 G/A, -725 C/G or C/T and -486 A/C are reported to be linked with an increased risk to develop an acute kidney allograft rejection being observed [135].

The 3'UTR region of the HLA-G gene is located distal of a stop codon in exon 6 meaning that exons 7 and 8 are not translated and missing in the mature mRNA. This region includes regulatory elements including AU-rich motifs and polyadenylation signals; and three important polymorphisms have been associated with the regulation of HLA-G expression.

First, the 14 bp fragment (5'-ATTTGTTCATGCCT-37) insertion or deletion has been associated with differences in the stability of the HLA-G mRNA [136]. The presence of the 14 bp insertion is related to increased stability of the transcript and with mechanisms of posttranscriptional control (alternative splicing), whereby 92 bases from the mature transcript are removed from the start of exon 8 [137]. Furthermore, there is the possibility of linkage disequilibrium (LD) among polymorphic sites in the 3'UTR with polymorphic sites in the 5'URR may leading to a different posttranscriptional patterns and changes in the HLA-G expression [128, 137, 138]. Importantly, mRNA from 14 bp insertion shows an increased surface expression of HLA-G1 expression relative to mRNA lacking the 14 bp sequence but the ratio of release sHLA-G1 to surface expressed HLA-G1 is lower [139]. In line with this, low sHLA-G levels are often associated with the 14 bp insertion genotype (+14/+14bp) in women having experienced pregnancy complications [140-143]. On the other hand in healthy individuals [144] and in heart transplantation, the highest production of sHLA-G has been related to the 14 bp deletion/deletion genotype in pre- and posttransplantation resulting in low rejection rates. In addition, the 14 bp polymorphism of the HLA-G gene is related to the cyclosporine absorption of the patient [145,146].

In bone marrow transplantation, although there are considerable evidences regarding the immunomodulation role of the HLA-G, only a few studies have evaluated the polymorphic sites in the HLA-G gene, particularly the 14 bp INDEL polymorphisms in the 3'UTR region. The 14 bp deletion homozygous genotype (-14/-14 bp) is associated with severe aGvHD, while the insertion homozygous genotype (+14/+14bp) and the heterozygous genotype (+14/-14bp) are associated with low risk for aGvHD in bone marrow transplantation for thalassemia patients [147]. Moreover, in HSCT recipients for hematologic malignancies, the homozygous insertion genotype +14/+14 bp was recently found to be associated with disease-free survival [148]. In contrast, the homozygous state for the 14 bp insertion presents a risk factor for severe aGvHD (grade III and IV) after HSCT using bone marrow as stem cell source from HLA-matched donors [149]. In two other studies the 14 bp INDEL allele and genotype frequencies revealed no significant differences in allo-HSCT posttransplantation complications such as acute or chronic GvHD [111,150].

Second, the small nucleotide polymorphism (SNP) at position +3142 C/G in the 3'UTR of the HLA-G gene is proposed to be a target for certain micro RNAs (miRNA), which results in degradation of the HLA-G mRNA. The presence of guanine at position +3142 may increase the affinity for miR-148a, miR-148b, and miR-152, which may downregulate the expression of HLA-G by RNA degradation or translation suppression [151,152].

Third, a SNP at the position +3187 A/G has been described recently. The presence of the +3187A allele causes decreased HLA-G expression because of its proximity to an AU-rich element related to mRNA degradation [153,154]. The +3187A allele maybe associated with pre-eclampsia [153].

In only one study all three polymorphic sites at 3'UTR have been analysed for kidney recipients. Among them the presence of the +3187A allele gives the highest association to acute and chronic rejections after kidney transplantation, whereas the others are only of marginal relevance [155].

Attempting to clarify the contradictory findings regarding HLA-G polymorphisms and disease associations it is interesting to point out that the presence of these two cited sites of polymorphisms besides the 14-bp polymorphism (+3142 C/G and +3187 A/G), both related with low mRNA availability, can be disposed in haplotypes and are possibly acting together at the HLA-G production scenario and might lead to different posttranscriptional patterns and changes in the HLA-G expression [132].

In conclusion, the impact of the genetic background on HLA-G expression in pregnancy and transplantation remains an open question. Further systematically evaluation of polymorphic sites in 57URR and 3'UTR and their relationship to the HLA-G/sHLA expression in allogeneic situation have to be performed to understand how HLA-G posttranscriptional mechanisms may contribute to tolerance. Under the assumption that the HLA-G expression is preferentially controlled by genetic factors, in transplantation the genetic background of both the donor and the recipient has to be taken into account. The donor type is of extraordinary importance as it should mirror the HLA-G expression in the graft, where the acute/chronic rejection actually takes place in solid organ transplantation. The genetic background of the recipient may control the expression by the recipient's effector cells for example, HLA-G expression on APC or release of sHLA-G molecules by alloreactive CD4 T cells, being related to long term inhibitory effects.

8. The Regulation of HLA-G Expression in Pregnancy and Transplantation

The genetic regulation of HLA-G expression differs from classical HLA class I molecules: the cis-regulatory elements that are present in the proximal promoter region of classical HLA class-I genes are altered in the HLA-G promoter region [156]. Upstream transcription initiation site three ras response elements [157] are located along the HLA-G 1.4 kb promoter region downregulating HLA-G after the binding of the ras responsive element binding 1 factor (RREB-1).

Evidence for epigenetic control of HLA-G is initially reported for seven different HLA-G negative tumor cell lines. The treatment of these cells with the demethylating agent 5-aza-2'-deoxycytidine results in the induction of HLA-G expression [158]. In general histone acetylation is usually associated with a relaxed chromatin structure and greater levels of gene expression. Consequently, HLA-G expressing cell lines revealed enhanced levels of histone acetylation in the HLA-G promoter chromatin having been reported to be significantly enhanced, whereas in HLA-G negative cell lines histones appeared to be hypomethylated [159-161].

Moreover, the 3'UTR region of HLA-G is suggested to be target for certain micro RNAs (miRNA), which results in degradation of the HLA-G mRNA. The binding of miR148a and miR-152 downregulates the expression of HLA-G by RNA degradation or translation suppression. Consequently, the ILT2 recognition and suppression of NK cell mediated killing is affected [162].

Regarding pregnancy and transplantation, a novel progesterone response element has been found leading to upregulation of HLA-G expression by progesterone [163] in trophoblasts [164], mesenchymal stem cells [165], and vascular endothelial and smooth muscle cells. Based on the latter observation progesterone is suggested to be a therapeutic option to protect against rejection and cardiac allograft vasculopathy after heart transplantation [166]. Interestingly, a computer search analysis has identified a putative consensus of hypoxia response element being located in the HLA-G promoter region. This might explain the 16-fold transcriptional upregulation of HLA-G by hypoxia induced via the iron chelator desferrioxamine [167]. Here, the relevance for ischemia reperfusion in transplanted organs has to be further investigated.

Among all cytokines and growth factors IFNs, IL10, and TGF[beta] appear primarily to be the most relevant factors influencing the HLA-G expression in an allergenic situation such as pregnancy or transplantation [168, 169]. Although the mechanistic background (for overview see [170]) is not fully clarified, HLA-G expression or the release of sHLA-G molecules are found to be upregulated in response of IFN-[alpha], IFN-[beta], and IFN-[gamma] by trophoblasts, blood, and tumor cells [18, 168, 171-173] as well as in response to IL-10 and TGF[beta] [169,174]. However, in any case basal transcriptional levels of HLA-G are essential for its upregulation [170]. With respect to HLA-G structures, a recent study has been evidenced that HLA-G1 and HLA-G5 dimerization are enhanced by microenvironmental factors such as IFN-[beta] or -[gamma] [175].

In context of transplantation, several studies indicate that immunosuppressive drugs influence the HLA-G expression: steroids such as dexamethasone and hydrocortisone upregulate the HLA-G transcription and protein expression [176-178]. In heart transplant patients the antiproliferative drug everolimus but not mycophenolate (MMF) has been associated to high sHLA-G levels. The calcineurin inhibitor cyclosporine (CSA) does not show any effect on HLA-G expression [179]. The treatment with Belatacept results in an increase ofsHLA-G levels. In vitro experiments have revealed that dendritic cells in the presence of Belatacept are able to secrete HLA-G, suggesting that HLA-G is involved in allograft acceptance [180]. Lastly, the antiproliferative agents Rapamycin induce ILT4 expression on DC and the release of sHLA-G molecules. These effects have been associated with an increase in the number of regulatory T cells and a shift of cytokine towards Th2 [181,182].

9. How Does HLA-G Offer Novel Therapeutic Perspectives in Transplantation?

The in vitro and in vivo data clearly demonstrate that HLAG is involved in the development of immune tolerance against allogeneic antigens, which can favour a successful transplantation. Thus, the next step should be to establish the therapeutic role of HLA-G. To this end functionally active HLA-G structures have to be produced compatible with good manufacturing practice (GMP) production conditions.

In a recent pilot study, two dimeric synthetic peptides have been engineered as therapeutic molecules. These peptides include either the alpha-3 domain of HLA-G alone or in combination with the alpha-1 domain. Both types of peptides are recognized by the ILT4 receptor but only the dimeric alpha-1/alpha-3 peptide has been found to be functional in vitro and in vivo active (Figure 2): one treatment of skin allograft recipient mice was sufficient to prolong graft survival, and four weekly treatments induce complete tolerance. In vitro experiments reveal that this peptide is able to inhibit the proliferation comparable to the dimeric full length HLA-G structure [183].

Another approach appears attractive and promising (Figure 2): to combine the function of HLA-G with the immune modulatory function of multipotent mesenchymal stem/stromal cells (MSCs). MSCs can be isolated from different tissues including bone marrow (BM), umbilical cord blood, adipose tissue, liver, and muscle. MSC has the ability to differentiate into osteoblasts, chondroblasts, or adipocytes in vitro and in vivo [184]. MSCs support the generation of damaged tissue by various factors including growth factors, cytokines and antioxidants [185]. In addition MSCs provide a broad complex spectrum to impair the innate and adaptive immune system. These immune modulatory functions of MSCs can be attributed to the secretion of soluble factors like indoleamine 2,3 dioxygenase (IDO), IL10, TGF[beta], prostaglandin E2 ([PEG.sub.2]), interleukin-1 receptor antagonist (IL-1RA), hepatocyte growth factor (HGF), insulin-like growth factor (IGF), leukemia inhibitory factor (LIF), and HLA-G5. The membrane expression of CD54, CD58, and HLA-G1 favours the generation and expansion of regulatory T cells (for review see 186,187]). HLA-G/sHLA-G expressed by MSCs participates in the inhibition of T cell proliferation in allogeneic situation and in the suppression of NK cell lysis via the KIR2DL4. Secretion of HLA-5 is boosted by the direct cell contact of MSCs and allogenic T cells. MSC supernatant containing HLA-G5 and IL-10 together are able to expand FoxP3 positive regulatory T cells [188]. Based on the pioneer study by Le Blanc et al. [189] MSCs have been suggested as a novel strategy to treat severe steroid-resistant grade IV acute GvHD patients. Although there is an overall concordance that the application of MSC is in principle safe, beneficial effects have been observed only in a portion of studies [190]. Thus, a good marker is required to ensure and improve the immune modulatory functions of MSCs. Here, HLA-G may serve as a candidate marker either to predict MSC functions or to isolate and expand specifically MSCs with strong immune suppressive properties. Interestingly, MCS are able to release immunological active extracellular vesicles such as exosomes [191]. Exosomes participate in the communication of cells and/or immune regulation (for overview see [192]). In a recent study [193] MSC-derived exosomes (Figure 2), harbouring large amount of HLA-G, IL-10 and TGF[beta], were used to treat a patient suffering from severe and therapy-refractory cutaneous and intestinal GvHD grade IV. After application the patient showed significantly improved clinical GvHD symptoms without any unwanted side-effects. Thus, this study represents the first treatment in humans, in which HLA-G with the immune modulatory function of MSC-derived exosomes has been applied. The clinical outcome clearly entitles further investigations.

10. Conclusion

Is HLA-G on the trail of a new panacea in allogeneic situations? If we accomplish to exploit this molecule's natural function, which prevents the embryo from being rejected while nesting in an alien surrounding, in situations like transplantation, HLA-G could bring a great improvement in reducing the burden of immunosuppressive drugs or in situations of therapy refractory alloimmune responses. Therefore mapping the different functional active structures of HLA-G and its relationship to the genetic and microenvironmental background is urgently needed to further define potential areas of application.

http://dx.doi.org/10.1155/2014/297073

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Acknowledgment

The publication of the paper was facilitated by the funding program "Open Access Publizieren" of the "Deutsche Forschungsgemeinschaft (DFG)."

References

[1] J. Robinson, J. A. Halliwell, H. McWilliam, R. Lopez, P. Parham, and S. G. E. Marsh, "The IMGT/HLA database," Nucleic Acids Research, vol. 41, no. 1, pp. D1222-D1227, 2013.

[2] N. Lee, A. R. Malacko, A. Ishitani et al., "The membrane-bound and soluble forms of HLA-G bind identical sets of endogenous peptides but differ with respect to TAP association," Immunity, vol. 3, no. 5, pp. 591-600, 1995.

[3] H. Nuckel, E. C. Castelli, P Moreau, C. Ochsenfarth, P A. Horn, and V. Rebmann, "Simple methods for the detection of HLA-G variants in coding and non-coding regions," Methods in Molecular Biology, vol. 882, pp. 123-142, 2012.

[4] P Paul, F. A. Cabestre, E. C. Ibrahim et al., "Identification of HLA-G7 as a new splice variant of the HLA-G mRNA and expression of soluble HLA-G5, -G6, and -G7 transcripts in human transfected cells," Human Immunology, vol. 61, no. 11, pp. 1138-1149, 2000.

[5] T. Fujii, A. Ishitani, and D. E. Geraghty, "A soluble form of the HLA-G antigen is encoded by a messenger ribonucleic acid containing intron 4," Journal of Immunology, vol. 153, no. 12, pp. 5516-5524, 1994.

[6] A. Ishitani and D. E. Geraghty, "Alternative splicing of HLA-G transcripts yields proteins with primary structures resembling both class I and class II antigens," Proceedings of the National Academy of Sciences of the United States of America, vol. 89, no. 9, pp. 3947-3951, 1992.

[7] D. E. Geraghty, B. H. Koller, and H. T. Orr, "A human major histocompatibility complex class I gene that encodes a protein with a shortened cytoplasmic segment.," Proceedings of the National Academy of Sciences of the United States of America, vol. 84, no. 24, pp. 9145-9149, 1987

[8] J. M. Houlihan, P A. Biro, H. M. Harper, H. J. Jenkinson, and C. H. Holmes, "The human amnion is a site of MHC class Ib expression: Evidence for the expression of HLA-E and HLA-G," Journal of Immunology, vol. 154, no. 11, pp. 5665-5674, 1995.

[9] A. Hammer, H. Hutter, A. Blaschitz et al., "Amnion epithelial cells, in contrast to trophoblast cells, express all classical HLA class I molecules together with HLA-G," American Journal of Reproductive Immunology, vol. 37, no. 2, pp. 161-171, 1997

[10] C. Menier, M. Rabreau, J. Challier, M. Le Discorde, E. D. Carosella, and N. Rouas-Freiss, "Erythroblasts secrete the nonclassical HLA-G molecule from primitive to definitive hematopoiesis," Blood, vol. 104, no. 10, pp. 3153-3160, 2004.

[11] A. Blaschitz, F. Lenfant, V. Mallet et al., "Endothelial cells in chorionic fetal vessels of first trimester placenta express HLA G, " European Journal of Immunology, vol. 27, no. 12, pp. 3380-3388, 1997

[12] L. Crisa, M. T. McMaster, J. K. Ishii, S. J. Fisher, and D. R. Salomon, "Identification of a thymic epithelial cell subset sharing expression of the class Ib HLA-G molecule with fetal trophoblasts," The Journal of Experimental Medicine, vol. 186, no. 2, pp. 289-298, 1997.

[13] M. Le Discorde, P. Moreau, P. Sabatier, J. Legeais, and E. D. Carosella, " Expression of HLA-G in human cornea, an immune-privileged tissue," Human Immunology, vol. 64, no. 11, pp. 1039-1044, 2003.

[14] V. Cirulli, J. Zalatan, M. McMaster et al., "The class I HLA repertoire of pancreatic islets comprises the nonclassical class Ib antigen HLA-G," Diabetes, vol. 55, no. 5, pp. 1214-1222,2006.

[15] T. Ito, N. Ito, M. Saathoff et al., "Immunology of the human nail apparatus: the nail matrix is a site of relative immune privilege," The Journal of Investigative Dermatology, vol. 125, no. 6,pp. 1139-1148, 2005.

[16] M. Ulbrecht, B. Rehberger, I. Strobel et al., "HLA-G: expression in human keratinocytes in vitro and in human skin in vivo," European Journal of Immunology, vol. 24, no. 1, pp. 176-180, 1994.

[17] V. Rebmann, K. Pfeiffer, M. Pafiler et al., "Detection of soluble HLA-G molecules in plasma and amniotic fluid," Tissue Antigens, vol. 53, no. 1, pp. 14-22, 1999.

[18] V. Rebmann, A. Busemann, M. Lindemann, and H. Grosse-Wilde, "Detection ofHLA-G5 secreting cells," Human Immunology, vol. 64, no. 11, pp. 1017-1024, 2003.

[19] V. Rebmann, J. LeMaoult, N. Rouas-Freiss, E. D. Carosella, and H. Grosse-Wilde, "Report of the Wet Workshop for quantification of soluble HLA-G in Essen, 2004," Human Immunology, vol. 66, no. 8, pp. 853-863, 2005.

[20] L. Zhao, B. Purandare, J. Zhang, and B. M. Hantash, "[beat]2-Microglobulin-free HLA-G activates natural killer cells by increasing cytotoxicity and proinflammatory cytokine production," Human Immunology, vol. 74, no. 4, pp. 417-424, 2013.

[21] T. Gonen-Gross, D. Goldman-Wohl, B. Huppertz et al., "Inhibitory NK receptor recognition of HLA-G: regulation by contact residues and by cell specific expression at the fetal-maternal interface," PLoS ONE, vol. 5, no. 1, Article ID e8941, 2010.

[22] A. Arnaiz-Villena, J. Martinez-Laso, J. I. Serrano-Vela, R. Reguera, and J. Moscoso, "HLA-G polymorphism and evolution," Tissue Antigens, vol. 69, supplement 1, pp. 156-159, 2007.

[23] J. E. Boyson, R. Erskine, M. C. Whitman et al., "Disulfide bond-mediated dimerization of HLA-G on the cell surface," Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 25, pp. 16180-16185, 2002.

[24] M. Shiroishi, K. Kuroki, L. Rasubala et al., "Structural basis for recognition of the nonclassical MHC molecule HLA-G by the leukocyte Ig-like receptor B2 (LILRB2/LIR2/ILT4/CD85d)," Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 44, pp. 16412-16417, 2006.

[25] K. Y. HoWangYin, M. Loustau, J. Wu et al., "Multimeric structures of HLA-G isoforms function through differential binding to LILRB receptors," Cellular and Molecular Life Sciences, vol. 69, no. 23, pp. 4041-4049, 2012.

[26] E. Alegre, V. Rebmann, J. Lemaoult et al., "In vivo identification of an HLA-G complex as ubiquitinated protein circulating in exosomes," European Journal of Immunology, vol. 43, no. 7, pp. 1933-1939, 2013.

[27] B. Riteau, F. Faure, C. Menier et al., "Exosomes Bearing HLA-G are Released by Melanoma Cells," Human Immunology, vol. 64, no. 11, pp. 1064-1072, 2003.

[28] M. Colonna, F. Navarro, T. Bellon et al., "A common inhibitory receptor for major histocompatibility complex class I molecules on human lymphoid and myelomonocytic cells," The Journal of Experimental Medicine, vol. 186, no. 11, pp. 1809-1818, 1997

[29] S. Rajagopalan and E. O. Long, "A human histocompatibility leukocyte antigen (HLA)-G-specific receptor expressed on all natural killer cells," Journal of Experimental Medicine, vol. 189, no. 7, pp. 1093-1100, 1999.

[30] D. Saverino, M. Fabbi, F. Ghiotto et al., "The CD85/LIR-1/ILT2 inhibitory receptor is expressed by all human T lymphocytes and down-regulates their functions," Journal of Immunology, vol. 165, no. 7, pp. 3742-3755, 2000.

[31] A. H. Banham, M. Colonna, M. Cella et al., "Identification of the CD85 antigen as ILT2, an inhibitory MHC class I receptor of the immunoglobulin superfamily," Journal of Leukocyte Biology, vol. 65, no. 6, pp. 841-845, 1999.

[32] D. L. Lamar, C. M. Weyand, and J. J. Goronzy, "Promoter choice and translational repression determine cell type-specific cell surface density of the inhibitory receptor CD85j expressed on different hematopoietic lineages," Blood, vol. 115, no. 16, pp. 3278-3286, 2010.

[33] M. Colonna, J. Samaridis, M. Cella et al., "Cutting edge: human myelomonocytic cells express an inhibitory receptor for classical and nonclassical MHC class I-molecules," Journal of Immunology, vol. 160, no. 7, pp. 3096-3100, 1998.

[34] C. S. Clements, L. Kjer-Nielsen, J. McCluskey, and J. Rossjohn, "Structural studies on HLA-G: implications for ligand and receptor binding," Human Immunology, vol. 68, no. 4, pp. 220-226, 2007.

[35] A. Verloes, H. van de Velde, J. leMaoult et al., "HLA-G expression in human embryonic stem cells and preimplantation embryos," Journal of Immunology, vol. 186, no. 4, pp. 2663-2671, 2011.

[36] W. H. Yan and L. A. Fan, "Residues Met76 and Gln79 in HLAG a1 domain involved in KIR2DL4 recognition," Cell Research, vol. 15, no. 3, pp. 176-182, 2005.

[37] J. P. Goodridge, C. S. Witt, F. T. Christiansen, and H. S. Warren, "KIR2DL4 (CD158d) genotype influences expression and function in NK cells," Journal of Immunology, vol. 171, no. 4, pp. 1768-1774, 2003.

[38] A. Kikuchi-Maki, S. Yusa, T. L. Catina, and K. S. Campbell, "KIR2DL4 is an IL-2-regulated NK cell receptor that exhibits limited expression in humans but triggers strong IFN-[gamma] production," Journal of Immunology, vol. 171, no. 7, pp. 3415-3425, 2003.

[39] N. M. Valiante, M. Uhrberg, H. G. Shilling et al., "Functionally and structurally distinct NK cell receptor repertoires in the peripheral blood of two human donors," Immunity, vol. 7, no. 6, pp. 739-751, 1997.

[40] Y. R. Yu, X. H. Tian, Y. Wang, and M. F Feng, "Rapid production of human KIR2DL4 extracellular domain and verification of its interaction with HLA-G," Biochemistry Biokhimiia, vol. 71, supplement 1, pp. S60-S65, 2006.

[41] S. Rajagopalan, Y. T. Bryceson, S. P. Kuppusamy et al., "Activation of NK cells by an endocytosed receptor for soluble HLA-G," PLoS Biology, vol. 4, article e9, 2006.

[42] S. Rajagopalan, J. Fu, and E. O. Long, "Cutting edge: induction of IFN-[gamma] production but not cytotoxicity by the killer cell Ig-like receptor KIR2DL4 (CD158d) in resting NK cells," Journal of Immunology, vol. 167, no. 4, pp. 1877-1881, 2001.

[43] M. E. Le Page, J. P. Goodridge, E. John, F. T. Christiansen, and C. S. Witt, "Response to comment on "Killer Ig-like receptor 2DL4 does not mediate NK cell IFN-gamma responses to soluble HLA-G preparations," The Journal of Immunology, vol. 192, no. 9, pp. 4003-4004, 2014.

[44] M. Brusilovsky, M. Cordoba, B. Rosental et al., "Genome-wide siRNA screen reveals a new cellular partner of NK cell receptor KIR2DL4: heparan sulfate directly modulates KIR2DL4mediated responses," The Journal of Immunology, vol. 191, no. 10, pp. 5256-5267, 2013.

[45] S. K. Sanders, P. A. Giblin, and P. Kavathas, "Cell-cell adhesion mediated by CD8 and human histocompatibility leukocyte antigen G, a nonclassical major histocompatibility complex class 1 molecule on cytotrophoblasts," The Journal of Experimental Medicine, vol. 174, no. 3, pp. 737-740,1991.

[46] P. Contini, M. Ghio, A. Poggi et al., "Soluble HLA-A,-B,-C and -G molecules induce apoptosis in T and NK CD8+ cells and inhibit cytotoxic T cell activity through CD8 ligation," European Journal of Immunology, vol. 33, no. 1, pp. 125-134, 2003.

[47] S. Fournel, M. Aguerre-Girr, X. Hucet al., "Cuttingedge: soluble HLA-G1 triggers CD95/CD95 ligand-mediated apoptosis in activated CD8+ cells by interacting with CD8," Journal of Immunology, vol. 164, no. 12, pp. 6100-6104, 2000.

[48] C. Solier, M. Aguerre-Girr, F Lenfant et al., "Secretion of pro-apoptotic intron 4-retaining soluble HLA-G1 by human villous trophoblast," European Journal of Immunology, vol. 32, no. 12, pp. 3576-3586, 2002.

[49] M. Llano, N. Lee, F. Navarro et al., "HLA-E-bound peptides influence recognition by inhibitory and triggering CD94/NKG2 receptors: preferential response to an HLA-G-derived nonamer," European Journal of Immunology, vol. 28, pp. 2854-2863, 1998.

[50] G. Curigliano, C. Criscitiello, L. Gelao, and A. Goldhirsch, "Molecular pathways: human leukocyte antigen G (HLA-G)," Clinical Cancer Research, vol. 19, pp. 5564-5571, 2013.

[51] S. Le Rond, C. Azema, I. Krawice-Radanne et al., "Evidence to support the role of HLA-G5 in allograft acceptance through induction of immunosuppressive/regulatory T cells," The Journal of Immunology, vol. 176, no. 5, pp. 3266-3276, 2006.

[52] S. Gregori, C. F. Magnani, and M. G. Roncarolo, "Role of human leukocyte antigen-G in the induction of adaptive type 1 regulatory T cells," Human Immunology, vol. 70, no. 12, pp. 966-969, 2009.

[53] N. Rouas-Freiss, A. Naji, A. Durrbach, and E. D. Carosella, "Tolerogenic functions of human leukocyte antigen G: from pregnancy to organ and cell transplantation," Transplantation, vol. 84, pp. S21-S25, 2007.

[54] M. Ponte, C. Cantoni, R. Biassoni et al., "Inhibitory receptors sensing HLA-G1 molecules in pregnancy: decidua- associated natural killer cells express LIR-1 and CD94/NKG2A and acquire p49, an HLA-G1-specific receptor," Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 10, pp. 5674-5679, 1999.

[55] B. Riteau, N. Rouas-Freiss, C. Menier, P. Paul, J. Dausset, and E. D. Carosella, "HLA-G2, -G3, and -G4 isoforms expressed as nonmature cell surface glycoproteins inhibit NK and antigen-specific CTL cytolysis," Journal of Immunology, vol. 166, no. 8, pp. 5018-5026, 2001.

[56] N. Rouas-Freiss, R. E. Marchal, M. Kirszenbaum, J. Dausset, and E. D. Carosella, "The a! domain of HLA-G1 and HLA-G2 inhibits cytotoxicity induced by natural killer cells: is HLA-G the public ligand for natural killer cell inhibitory receptors?" Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 10, pp. 5249-5254, 1997

[57] N. Rouas-Freiss, R. M. Gonsalves, C. Menier, J. Dausset, and E. D. Carosella, "Direct evidence to support the role of HLAG in protecting the fetus from maternal uterine natural killer cytolysis," Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 21, pp. 11520-11525, 1997.

[58] B. Riteau, C. Menier, I. Khalil-Daher et al., "HLA-G inhibits the allogeneic proliferative response," Journal of Reproductive Immunology, vol. 43, no. 2, pp. 203-211, 1999.

[59] F. Ketroussi, M. Giuliani, R. Bahri, B. Azzarone, B. Charpentier, and A. Durrbach, "Lymphocyte cell-cycle inhibition by HLAG is mediated by phosphatase SHP-2 and acts on the mTOR pathway," PLoS ONE, vol. 6, no. 8, Article ID e22776, 2011.

[60] R. Bahri, F. Hirsch, A. Josse et al., "Soluble HLA-G inhibits cell cycle progression in human alloreactive T lymphocytes," Journal of Immunology, vol. 176, no. 3, pp. 1331-1339, 2006.

[61] A. Naji, C. Menier, F. Morandi et al., "Binding of HLA-G to ITIM-bearing Ig-like transcript 2 receptor suppresses B cell responses," The Journal of Immunology, vol. 192, no. 4, pp. 1536-1546, 2014.

[62] T. Kanai, T. Fujii, N. Unno et al., "Human leukocyte antigen-G-expressing cells differently modulate the release of cytokines from mononuclear cells present in the decidua versus peripheral blood," The American Journal of Reproductive Immunology, vol. 45, no. 2, pp. 94-99, 2001.

[63] T. Kanai, T. Fujii, S. Kozuma et al., "Soluble HLA-G influences the release of cytokines from allogeneic peripheral blood mononuclear cells in culture," Molecular Human Reproduction, vol. 7, no. 2, pp. 195-200, 2001.

[64] S. Liang, B. Baibakov, and A. Horuzsko, "HLA-G inhibits the functions of murine dendritic cells via the PIR-B immune inhibitory receptor," European Journal of Immunology, vol. 32, pp. 2418-2426, 2002.

[65] S. Liang, V. Ristich, H. Arase, J. Dausset, E. D. Carosella, and A. Horuzsko, "Modulation of dendritic cell differentiation by HLA-G and ILT4 requires the IL-6-STAT3 signaling pathway," Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 24, pp. 8357-8362, 2008.

[66] W. Zhang, S. Liang, J. Wu, and A. Horuzsko, "Human inhibitory receptor immunoglobulin-like transcript 2 amplifies CD11b+Gr1+ myeloid-derived suppressor cells that promote long-term survival of allografts," Transplantation, vol. 86, no. 8, pp. 1125-1134, 2008.

[67] J. LeMaoult, I. Krawice-Radanne, J. Dausset, and E. D. Carosella, "HLA-G1-expressing antigen-presenting cells induce immunosuppressive CD4+ T cells," Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 18, pp. 7064-7069, 2004.

[68] S. Gregori, D. Tomasoni, V. Pacciani et al., "Differentiation of type 1 T regulatory cells (Tr1) by tolerogenic DC-10 requires the IL-10-dependent ILT4/HLA-G pathway," Blood, vol. 116, pp. 935-944, 2010.

[69] M. Rossetti, S. Gregori, and M. G. Roncarolo, "Granulocytecolony stimulating factor drives the in vitro differentiation of human dendritic cells that induce anergy in naive T cells," European Journal of Immunology, vol. 40, no. 11, pp. 3097-3106, 2010.

[70] G. Amodio, A. Mugione, A. M. Sanchez et al., "HLA-G expressing DC-10 and CD4+ T cells accumulate in human decidua during pregnancy," Human Immunology, vol. 74, no. 4, pp. 406-411, 2013.

[71] Y. Q. Yao, D. H. Barlow, and I. L. Sargent, "Differential expression of alternatively spliced transcripts of HLA-G in human preimplantation embryos and inner cell masses," Journal of Immunology, vol. 175, no. 12, pp. 8379-8385, 2005.

[72] V. R. Shaikly, I. E. G. Morrison, M. Taranissi et al., "Analysis of HLA-G in maternal plasma, follicular fluid, and preimplantation embryos reveal an asymmetric pattern of expression," Journal of Immunology, vol. 180, no. 6, pp. 4330-4337, 2008.

[73] A. Jurisicova, R. F. Casper, N. J. MacLusky, and C. L. Librach, "Embryonic human leukocyte antigen-G expression: possible implications for human preimplantation development," Fertility and Sterility, vol. 65, no. 5, pp. 997-1002, 1996.

[74] A. Jurisicova, R. F. Casper, N. J. Maclusky, G. B. Mills, and C. L. Librach, "HLA-G expression during preimplantation human embryo development," Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 1, pp. 161-165, 1996.

[75] A. Gonzalez, V. Rebmann, J. Lemaoult, P. A. Horn, E. D. Carosella, and E. Alegre, "The immunosuppressive molecule HLA-G and its clinical implications," Critical Reviews in Clinical Laboratory Sciences, vol. 49, no. 3, pp. 63-84, 2012.

[76] R. Rizzo, M. Vercammen, H. van de Velde, P. A. Horn, and V. Rebmann, "The importance of HLA-G expression in embryos, trophoblast cells, and embryonic stem cells," Cellular and Molecular Life Sciences, vol. 68, no. 3, pp. 341-352, 2011.

[77] M. Dahl and T. V. F. Hviid, "Human leucocyte antigen class Ib molecules in pregnancy success and early pregnancy loss," Human Reproduction Update, vol. 18, no. 1, pp. 92-109, 2012.

[78] V. Rebmann, M. Switala, I. Eue, and H. Grosse-Wilde, "Soluble HLA-G is an independent factor for the prediction of pregnancy outcome after ART: a German multi-centre study," Human Reproduction, vol. 25, no. 7, pp. 1691-1698, 2010.

[79] A. Ishitani, N. Sageshima, and K. Hatake, "The involvement of HLA-E and -F in pregnancy," Journal of Reproductive Immunology, vol. 69, no. 2, pp. 101-113, 2006.

[80] A. Ishitani, N. Sageshima, N. Lee et al., "Protein expression and peptide binding suggest unique and interacting functional roles for HLA-E, F, and G in maternal-placental immune recognition," Journal of Immunology, vol. 171, no. 3, pp. 1376-1384, 2003.

[81] R. G. Roussev and C. B. Coulam, "HLA-G and its role in implantation (review)," Journal of Assisted Reproduction and Genetics, vol. 24, no. 7, pp. 288-295, 2007.

[82] R. Apps, L. Gardner, A. M. Sharkey, N. Holmes, and A. Moffett, "A homodimeric complex of HLA-G on normal trophoblast cells modulates antigen-presenting cells via LILRB1," European Journal of Immunology, vol. 37, no. 7, pp. 1924-1937, 2007

[83] P. J. Morales, J. L. Pace, J. S. Platt, D. K. Langat, and J. S.

Hunt, "Synthesis of [beta]2-microglobulin-free, disulphide-linked HLAG5 homodimers in human placental villous cytotrophoblast cells," Immunology, vol. 122, no. 2, pp. 179-188, 2007.

[84] L. Lombardelli, M. Aguerre-Girr, F. Logiodice et al., "Piccinni MP: HLA-G5 induces IL-4 secretion critical for successful pregnancy through differential expression of ILT2 receptor on decidual CD4(+) T cells and macrophages," Journal of Immunology, vol. 191, pp. 3651-3662, 2013.

[85] Y. H. Huang, A. L. Zozulya, C. Weidenfeller et al., "Specific central nervous system recruitment of HLA-G+ regulatory T cells in multiple sclerosis," Annals of Neurology, vol. 66, no. 2, pp. 171-183, 2009.

[86] D. S. Goldman-Wohl, I. Ariel, C. Greenfield et al., "Lack of human leukocyte antigen-G expression in extravillous trophoblasts is associated with pre-eclampsia," Molecular Human Reproduction, vol. 6, no. 1, pp. 88-95, 2000.

[87] A. Farina, C. Zucchini, P. De Sanctis et al., "Gene expression in chorionic villous samples at 11 weeks of gestation in women who develop pre-eclampsia later in pregnancy: implications for screening," Prenatal Diagnosis, vol. 31, no. 2, pp. 181-185, 2011.

[88] N. Hara, T. Fujii, T. Yamashita, S. Kozuma, T. Okai, and Y. Taketani, "Altered expression of human leukocyte antigen g (HLA-G) on extravillous trophoblasts in preeclampsia: Immunohistological demonstration with anti-HLA-G specific antibody "87G" and anti-cytokeratin antibody 'CAM5.2,' The American Journal of Reproductive Immunology, vol. 36, no. 6, pp. 349-358, 1996.

[89] S. M. Yie, L. H. Li, Y. M. Li, and C. Librach, "HLA-G protein concentrations in maternal serum and placental tissue are decreased in preeclampsia," The American Journal of Obstetrics and Gynecology, vol. 191, no. 2, pp. 525-529, 2004.

[90] J. S. Hunt, L. Jadhav, W. Chu, D. E. Geraghty, and C. Ober, "Soluble HLA-G circulates in maternal blood during pregnancy," The American Journal of Obstetrics and Gynecology, vol. 183, no. 3, pp. 682-688, 2000.

[91] E. Alegre, A. Diaz-Lagares, J. LeMaoult, N. Lopez-Moratalla, E. D. Carosella, and A. Gonzalez, "Maternal antigen presenting cells are a source of plasmatic HLA-G during pregnancy: longitudinal study during pregnancy," Human Immunology, vol. 68, no. 8, pp. 661-667, 2007.

[92] R. Hackmon, M. Hallak, M. Krup et al., "HLA-G antigen and parturition: maternal serum, fetal serum and amniotic fluid levels during pregnancy," Fetal Diagnosis and Therapy, vol. 19, no. 5, pp. 404-409, 2004.

[93] J. P. Kusanovic, R. Romero, C. Jodicke et al., "Amniotic fluid soluble human leukocyte antigen-G in term and preterm parturition, and intra-amniotic infection/inflammation," Journal of Maternal-Fetal and Neonatal Medicine, vol. 22, no. 12, pp. 1151-1166, 2009.

[94] N. Lila, A. Carpentier, C. Amrein, I. Khalil-Daher, J. Dausset, and E. D. Carosella, "Implication of HLA-G molecule in heart-graft acceptance," The Lancet, vol. 355, no. 9221, p. 2138, 2000.

[95] N. Lila, C. Amrein, R. Guillemain et al., "Human leukocyte antigen-G expression after heart transplantation is associated with a reduced incidence of rejection," Circulation, vol. 105, no. 16, pp. 1949-1954, 2002.

[96] J. Luque, M. I. Torres, M. D. Aumente et al., "Soluble HLA-G in heart transplantation: their relationship to rejection episodes and immunosuppressive therapy," Human Immunology, vol. 67, no. 4-5, pp. 257-263, 2006.

[97] R. Sheshgiri, V. Rao, A. Mociornita, H. J. Ross, and D. H. Delgado, "Association between HLA-G expression and C4d staining in cardiac transplantation," Transplantation, vol. 89, no. 4, pp. 480-481, 2010.

[98] N. Lila, N. Rouas-Freiss, J. Dausset, A. Carpentier, and E. D. Carosella, "Soluble HLA-G protein secreted by allo-specific CD4+ T cells suppresses the allo-proliferative response: a CD4+ T cell regulatory mechanism," Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 21, pp. 12150-12155, 2001.

[99] R. M. Blanco-Garcia, M. R. Lopez-alvarez, I. P Garrido et al., "Post-transplant increase in soluble human leukocyte antigen-G associated with non-severe cardiac allograft vasculopathy," Human Immunology, vol. 74, no. 3, pp. 318-324, 2013.

[100] A. G. Mociornita, J. Lim-Shon, J. M. Joseph, H. J. Ross, V. Rao, and D. H. Delgado, "Can HLA-G polymorphisms predict the development of cardiac allograft vasculopathy?" Human Immunology, vol. 74, no. 4, pp. 464-467, 2013.

[101] S. Le Rond, J. Le Maoult, C. Creput et al., "Alloreactive CD4+ and CD8+ T cells express the immunotolerant HLA-G molecule in mixed lymphocyte reactions: in vivo implications in transplanted patients," European Journal of Immunology, vol. 34, no. 3, pp. 649-660, 2004.

[102] C. Creput, A. Durrbach, C. Menier et al., "Human leukocyte antigen-G (HLA-G) expression in biliary epithelial cells is associated with allograft acceptance in liver-kidney transplantation," Journal of Hepatology, vol. 39, no. 4, pp. 587-594, 2003.

[103] O. Brugiere, G. Thabut, M. Pretolani et al., "Immunohistochemical study of HLA-G expression in lung transplant recipients," The American Journal of Transplantation, vol. 9, no. 6, pp. 1427-1438, 2009.

[104] A. Naji, S. Le Rond, A. Durrbach et al., "CD3+CD4 low and CD3+CD8 low are induced by HLA-G: novel human peripheral blood suppressor T-cell subsets involved in transplant acceptance," Blood, vol. 110, no. 12, pp. 3936-3948, 2007

[105] V. Zarkhin, A. Talisetti, L. Li et al., "Expression of soluble HLAG identifies favorable outcomes in liver transplant recipients," Transplantation, vol. 90, no. 9, pp. 1000-1005, 2010.

[106] B. Basturk, F. Karakayali, R. Emiroglu et al., "Human leukocyte antigen-G, a new parameter in the follow-up of liver transplantation," Transplantation Proceedings, vol. 38, no. 2, pp. 571-574, 2006.

[107] V. Rebmann, D. Bartsch, A. Wunsch et al., "Soluble total human leukocyte antigen class I and human leukocyte antigenG molecules in kidney and kidney/pancreas transplantation," Human Immunology, vol. 70, no. 12, pp. 995-999, 2009.

[108] H. Kaneku, "Detection of soluble HLA-G and its correlation with kidney transplant outcome," Clinical Transplants, pp. 447-454, 2006.

[109] H. Liu, Y. Chen, L. Xuan et al., "Soluble human leukocyte antigen G molecule expression in allogeneic hematopoietic stem cell transplantation: good predictor of acute graft-versus-host disease," Acta Haematologica, vol. 130, no. 3, pp. 160-168, 2013.

[110] A. Le Maux, G. Noel, B. Birebent et al., "Soluble human leucocyte antigen-G molecules in peripheral blood haematopoietic stem cell transplantation: a specific role to prevent acute graft-versus-host disease and a link with regulatory T cells," Clinical and Experimental Immunology, vol. 152, no. 1, pp. 50-56, 2008.

[111] M. Waterhouse, J. Duque-Afonso, R. Wasch, H. Bertz, and J. Finke, "Soluble HLA-G molecules and HLA-G 14-base pair polymorphism after allogeneic hematopoietic cell transplantation," Transplantation Proceedings, vol. 45, no. 1, pp. 397-401, 2013.

[112] K. van derVen andC. Ober, "HLA-Gpolymorphismsin African Americans," Journal of Immunology, vol. 153, no. 12, pp. 5628-5633, 1994.

[113] M. Le Discorde, C. Le Danff, P Moreau, N. Rouas-Freiss, and E. D. Carosella, "HLA-G*0105N null allele encodes functional HLA-G isoforms," Biology of Reproduction, vol. 73, no. 2, pp. 280-288, 2005.

[114] J. Lajoie, A. Boivin, A. Jeanneau, M. Faucher, and M. Roger, "Identification of six new HLA-G alleles with non-coding DNA base changes," Tissue Antigens, vol. 73, no. 4, pp. 379-380, 2009.

[115] C. Matte, J. Lacaille, L. Zijenah et al., "HLA-G and HLA-E polymorphisms in an indigenous african population," Human Immunology, vol. 61, no. 11, pp. 1150-1156, 2000.

[116] A. Abbas, P. Tripathi, S. Naik, and S. Agrawal, "Analysis of human leukocyte antigen (HLA)-G polymorphism in normal women and in women with recurrent spontaneous abortions," European Journal ofImmunogenetics, vol. 31, no. 6, pp. 275-278, 2004.

[117] E. A. Donadi, E. C. Castelli, A. Arnaiz-Villena, M. Roger, D. Rey, and P. Moreau, "Implications of the polymorphism of HLA-G on its function, regulation, evolution and disease association," Cellular and Molecular Life Sciences, vol. 68, no. 3, pp. 369-395, 2011.

[118] C. Czarnecki, G. Van Domselaar, J. Embree, R. Brunham, F. A. Plummer, and M. Luo, "Identification of HLA-G*01:17, a new allele possibly generated by an interloci gene conversion event involving exon 3 of HLA-B," Human Immunology, vol. 72, pp. 238-240, 2011.

[119] J. Roger, M.-C. Faucher, and M. Roger, "Identification of a new HLA-G allele, HLA-G*01:18, in a Canadian Caucasian individual," Tissue Antigens, vol. 80, no. 5, pp. 472-473, 2012.

[120] I. Cervera, M. A. Herraiz, A. Roman, J. Vidart, and J. Martinez-Laso, "The novel HLA-G*01010302 allele differs from G* 01010301 by a single nucleotide change in intron 5," Tissue Antigens, vol. 74, no. 5, pp. 463-464, 2009.

[121] I. Cervera, M. A. Herraiz, J. Penaloza, J. Vidart, and J. Martinez-Laso, "The novel HLA-G*01:03:01:02 allele differs from G*01:03:01:01 by a possible inversion event in intron 3," Tissue Antigens, vol. 78, no. 2, pp. 159-160, 2011.

[122] A. Roman, I. Cervera, M. A. Herraiz, J. Vidart, and J. Martinez-Laso, "A new allele, HLA-G*01010106, with changes in intron 2," Tissue Antigens, vol. 74, pp. 270-271, 2009.

[123] V. Rebmann, K. van derVen, M. Pafiler, K. Pfeiffer, D. Krebs, and H. Grosse-Wilde, "Association of soluble HLA-G plasma levels with HLA-G alleles," Tissue Antigens, vol. 57, no. 1, pp. 15-21, 2001.

[124] G. Mueller-Eckhardt, P. Mallmann, J. Neppert et al., "Immunogenetic and serological investigations in nonpregnant and in pregnant women with a history of recurrent spontaneous abortions," Journal of Reproductive Immunology, vol. 27, no. 2, pp. 95-109, 1994.

[125] C. L. Aldrich, M. D. Stephenson, T. Karrison et al., "HLA-G genotypes and pregnancy outcome in couples with unexplained recurrent miscarriage," Molecular Human Reproduction, vol. 7, no. 12, pp. 1167-1172, 2001.

[126] A. Pirri, F. C. Contieri, R. Benvenutti, and M. D. G. Bicalho, "A study of HLA-G polymorphism and linkage disequilibrium in renal transplant patients and their donors," Transplant Immunology, vol. 20, no. 3, pp. 143-149, 2009.

[127] T. V. F. Hviid, R. Rizzo, L. Melchiorri, M. Stignani, and O. R. Baricordi, "Polymorphism in the 5' Upstream Regulatory and 3; Untranslated Regions ofthe HLA-G Gene in Relation to Soluble HLA-G and IL-10 Expression," Human Immunology, vol. 67, no. 1-2, pp. 53-62, 2006.

[128] E. C. Castelli, C. T. Mendes-Junior, N. H. S. Deghaide et al., "The genetic structure of 3/untranslated region of the HLA-G gene: polymorphisms and haplotypes," Genes & Immunity, vol. 11, no. 2, pp. 134-141, 2010.

[129] S. J. P. Gobin, V. Keijsers, C. Cheong, M. van Zutphen, and P. J. van den Elsen, "Transcriptional regulation of HLA-G," Transplantation Proceedings, vol. 31, no. 4, pp. 1857-1859, 1999.

[130] C. Solier, V. Mallet, F. Lenfant, A. Bertrand, A. Huchenq, and P. Le Bouteiller, "HLA-G unique promoter region: functional implications," Immunogenetics, vol. 53, no. 8, pp. 617-625, 2001.

[131] Z. Tan, A. M. Shon, and C. Ober, "Evidence of balancing selection at the HLA-G promoter region," Human Molecular Genetics, vol. 14, no. 23, pp. 3619-3628, 2005.

[132] T. V. F. Hviid, S. Hylenius, C. Rorbye, and L. G. Nielsen, "HLA-G allelic variants are associated with differences in the HLA-G mRNA isoform profile and HLA-G mRNA levels," Immunogenetics, vol. 55, no. 2, pp. 63-79, 2003.

[133] C. Ober, C. L. Aldrich, I. Chervoneva et al., "Variation in the HLA-G promoter region influences miscarriage rates," The American Journal of Human Genetics, vol. 72, no. 6, pp. 1425-1435, 2003.

[134] D. S. Berger, W. A. Hogge, M. M. Barmada, and R. E. Ferrell, "Comprehensive analysis of HLA-G: implications for recurrent spontaneous abortion," Reproductive Sciences, vol. 17, no. 4, pp. 331-338, 2010.

[135] M. K. Misra, S. Prakash, R. Kapoor, S. K. Pandey, R. K. Sharma, and S. Agrawal, "Association of HLA-G promoter and 14-bp insertion-deletion variants with acute allograft rejection and end-stage renal disease," Tissue Antigens, vol. 82, pp. 317-326, 2013.

[136] G. A. Harrison, K. E. Humphrey, I. B. Jakobsen, and D. W. Cooper, "A 14 bp deletion polymorphism in the HLA-G gene," Human Molecular Genetics, vol. 2, no. 12, article 2200, 1993.

[137] P. Rousseau, M. le Discorde, G. Mouillot, C. Marcou, E. D. Carosella, and P. Moreau, "The 14 bp deletion-insertion polymorphism in the 3' UT region of the HLA-G gene influences HLA-G mRNA stability," Human Immunology, vol. 64, no. 11, pp. 1005-1010, 2003.

[138] D. Auboeuf, A. Honig, S. M. Berget, and B. W. O'Malley, "Coordinate regulation of transcription and splicing by steroid receptor coregulators," Science, vol. 298, no. 5592, pp. 416-419, 2002.

[139] S. G. Svendsen, B. M. Hantash, L. Zhao et al., "The expression and functional activity of membrane-bound human leukocyte antigen-G1 are influenced by the 3/-untranslated region," Human Immunology, vol. 74, no. 7, pp. 818-827, 2013.

[140] T. V. F. Hviid, R. Rizzo, O. B. Christiansen, L. Melchiorri, A. Lindhard, and O. R. Baricordi, "HLA-G and IL-10 in serum in relation to HLA-G genotype and polymorphisms," Immunogenetics, vol. 56, no. 3, pp. 135-141, 2004.

[141] T. V Hviid, S. Hylenius, A. M. Hoegh, C. Kruse, and O. B. Christiansen, "HLA-G polymorphisms in couples with recurrent spontaneous abortions," Tissue Antigens, vol. 60, no. 2, pp. 122-132, 2002.

[142] X. Wang, W. Jiang, and D. Zhang, "Association of 14-bp insertion/deletion polymorphism of HLA-G gene with unexplained recurrent spontaneous abortion: a meta-analysis," Tissue Antigens, vol. 81, no. 2, pp. 108-115, 2013.

[143] W. Fan, S. Li, Z. Huang, and Q. Chen, "Relationship between HLA-G polymorphism and susceptibility to recurrent miscarriage: a meta-analysis of non-family-based studies," Journal of Assisted Reproduction and Genetics, vol. 31, no. 2, pp. 173-184, 2014.

[144] G. Martelli-Palomino, J. A. Pancotto, Y. C. Muniz et al., "Polymorphic sites at the 3; untranslated region of the HLA-G gene are associated with differential hla-g soluble levels in the Brazilian and French population," PLoS ONE, vol. 8, Article ID e71742, 2013.

[145] M. I. Torres, J. Luque, P. Lorite et al., "14-Base pair polymorphism of human leukocyte antigen-G as genetic determinant in heart transplantation and cyclosporine therapy monitoring," Human Immunology, vol. 70, no. 10, pp. 830-835, 2009.

[146] T. Twito, J. Joseph, A. Mociornita, V. Rao, H. Ross, and D. H. Delgado, "The 14-bp deletion in the HLA-G gene indicates a low risk for acute cellular rejection in heart transplant recipients," The Journal of Heart and Lung Transplantation, vol. 30, no. 7, pp. 778-782, 2011.

[147] G. La Nasa, R. Littera, F. Locatelli et al., "The human leucocyte antigen-G 14-basepair polymorphism correlates with graft-versus-host disease in unrelated bone marrow transplantation for thalassaemia," The British Journal of Haematology, vol. 139, no. 2, pp. 284-288, 2007.

[148] P. Chiusolo, S. Bellesi, N. Piccirillo et al., "The role of HLA-G 14bp polymorphism in allo-HSCT after short-term course MTX for GvHD prophylaxis," Bone Marrow Transplantation, vol. 47, no. 1, pp. 120-124, 2012.

[149] W. Boukouaci, M. Busson, C. Fortier et al., "Association of HLAG low expressor genotype with severe acute graft-versus-host disease after sibling bone marrow transplantation," Frontiers in Immunology, vol. 2, article 74, 2011.

[150] F. Sizzano, M. Testi, L. Zito et al., "Genotypes and haplotypes

in the 31 untranslated region of the HLA-G gene and their association with clinical outcome of hematopoietic stem cell transplantation for beta-thalassemia," Tissue Antigens, vol. 79, no. 5, pp. 326-332, 2012.

[151] Z. Tan, G. Randall, J. Fan et al., "Allele-specific targeting of microRNAs to HLA-G and risk of asthma," The American Journal of Human Genetics, vol. 81, no. 4, pp. 829-834, 2007.

[152] T. D. Veit and J. A. B. Chies, "Tolerance versus immune response--microRNAs as important elements in the regulation ofthe HLA-G gene expression," Transplant Immunology, vol. 20, no. 4, pp. 229-231, 2009.

[153] S.-M. Yie, L.-H. Li, R. Xiao, and C. L. Librach, "A single base-pair mutation in the 3'-untranslated region of HLA-G mRNA is associated with pre-eclampsia," Molecular Human Reproduction, vol. 14, no. 11, pp. 649-653, 2008.

[154] E. C. Castelli, P. Moreau, A. O. E. Chiromatzo et al., "In silico analysis of microRNAS targeting the HLA-G 3; untranslated region alleles and haplotypes," Human Immunology, vol. 70, no. 12, pp. 1020-1025, 2009.

[155] D. C. Ciliao Alves, J. C. De Oliveira Crispim, E. C. Castelli et al., "Human leukocyte antigen-G 3; untranslated region polymorphisms are associated with better kidney allograft acceptance," Human Immunology, vol. 73, no. 1, pp. 52-59,2012.

[156] S. J. P. Gobin and P. J. van den Elsen, "Transcriptional regulation of the MHC class Ib genes HLA-E, HLA-F and HLA-G," Human Immunology, vol. 61, no. 11, pp. 1102-1107, 2000.

[157] S. Flajollet, I. Poras, E. D. Carosella, and P. Moreau, "RREB-1 is a transcriptional repressor of HLA-G," Journal of Immunology, vol. 183, no. 11, pp. 6948-6959, 2009.

[158] P. Moreau, G. Mouillot, P. Rousseau, C. Marcou, J. Dausset, and E. D. Carosella, "HLA-G gene repression is reversed by demethylation," Proceedings ofthe National Academy of Sciences of the United States of America, vol. 100, no. 3, pp. 1191-1196, 2003.

[159] G. Mouillot, C. Marcou, P. Rousseau, N. Rouas-Freiss, E. D. Carosella, and P. Moreau, "HLA-G gene activation in tumor cells involves cis-acting epigenetic changes," International Journal of Cancer, vol. 113, no. 6, pp. 928-936, 2005.

[160] K. Polakova, E. Bandzuchova, J. Tirpakova, D. Kuba, and G. Russ, "Modulation of HLA-G expression," Neoplasma, vol. 54, no. 6, pp. 455-462, 2007.

[161] T. M. Holling, M. W. T. Bergevoet, R. J. Wierda, M. C. J. A. van Eggermond, and P. J. van den Elsen, "Genetic and epigenetic control of the major histocompatibility complex class Ib Gene HLA-G in Trophoblast cell lines," Annals of the New York Academy of Sciences, vol. 1173, pp. 538-544, 2009.

[162] I. Manaster, D. Goldman-Wohl, C. Greenfield et al., "MiRNA-mediated control of HLA-G expression and function," PLoS ONE, vol. 7, no. 3, Article ID e33395, 2012.

[163] S. M. Yie, R. Xiao, and C. L. Librach, "Progesterone regulates HLA-G gene expression through a novel progesterone response element," Human Reproduction, vol. 21, no. 10, pp. 2538-2544, 2006.

[164] S. Yie, L. Li, G. Li, R. Xiao, and C. L. Librach, "Progesterone enhances HLA-G gene expression in JEG-3 choriocarcinoma cells and human cytotrophoblasts in vitro," Human Reproduction, vol. 21, no. 1, pp. 46-51, 2006.

[165] D. S. Kyurkchiev, E. Ivanova-Todorova, and S. D. Kyurkchiev, "Effect of progesterone on human mesenchymal stem cells," Vitamins and Hormones, vol. 87, pp. 217-237, 2011.

[166] R. Sheshgiri, V. Rao, L. C. Tumiati et al., "Progesterone induces human leukocyte antigen-g expression in vascular endothelial and smooth muscle cells.," Circulation, vol. 118, no. 14, pp. S58S64, 2008.

[167] G. Mouillot, C. Marcou, I. Zidi et al., "Hypoxia modulates HLAG gene expression in tumor cells," Human Immunology, vol. 68, no. 4, pp. 277-285, 2007.

[168] Y. Yang, D. E. Geraghty, and J. S. Hunt, "Cytokine regulation of HLA-G expression in human trophoblast cell lines," Journal of Reproductive Immunology, vol. 29, no. 3, pp. 179-195, 1995.

[169] P. Moreau, F. Adrian-Cabestre, C. Menier et al., "IL-10 selectively induces HLA-G expression in human trophoblasts and monocytes," International Immunology, vol. 11, no. 5, pp. 803-811, 1999.

[170] P. Moreau, S. Flajollet, and E. D. Carosella, "Non-classical transcriptional regulation of HLA-G: an update," Journal of Cellular and Molecular Medicine, vol. 13, no. 9, pp. 2973-2989, 2009.

[171] S. Lefebvre, S. Berrih-Aknin, F. Adrian et al., "A specific interferon (IFN)-stimulated response element of the distal HLA-G promoter binds IFN-regulatory factor 1 and mediates enhancement of this nonclassical class I gene by IFN-[beta]," The Journal of Biological Chemistry, vol. 276, no. 9, pp. 6133-6139, 2001.

[172] V. Rebmann, J. Regel, D. Stolke, and H. Grosse-Wilde, "Secretion of sHLA-G molecules in malignancies," Seminars in Cancer Biology, vol. 13, no. 5, pp. 371-377, 2003.

[173] S. Ugurel, V.Rebmann, S. Ferrone, W. Tilgen, H. Grosse-Wilde, and U. Reinhold, "Soluble human leukocyte antigen--G serum level is elevated in melanoma patients and is further increased by interferon-alpha immunotherapy," Cancer, vol. 92, pp. 369-376, 2001.

[174] P. Cadet, P. L. Rady, S. K. Tyring, R. B. Yandell, and T. K. Hughes, "Interleukin-10 messenger ribonucleic acid in human placenta: implications of a role for interleukin-10 in fetal allograft protection," The American Journal of Obstetrics and Gynecology, vol. 173, no. 1, pp. 25-29, 1995.

[175] S. Zilberman, C. Schenowitz, S. Agaugue et al., "HLA-G1 and HLA-G5 active dimers are present in malignant cells and effusions: the influence of the tumor microenvironment," European Journal of Immunology, vol. 42, no. 6, pp. 1599-1608, 2012.

[176] P. Moreau, O. Faure, S. Lefebvre et al., "Glucocorticoid hormones upregulate levels of HLA-G transcripts in trophoblasts," Transplantation Proceedings, vol. 33, no. 3, pp. 2277-2280, 2001.

[177] A. Akhter, R. M. Faridi, V. Das, A. Pandey, S. Naik, and S. Agrawal, "In vitro up-regulation of HLA-G using dexamethasone and hydrocortisone in first-trimester trophoblast cells of women experiencing recurrent miscarriage," Tissue Antigens, vol. 80, no. 2, pp. 126-135, 2012.

[178] A. Akhter, V. Das, S. Naik, R. M. Faridi, A. Pandey, and S. Agrawal, "Upregulation of HLA-G in JEG-3 cells by dexamethasone and hydrocortisone," Archives of Gynecology and Obstetrics, vol. 285, no. 1, pp. 7-14, 2012.

[179] R. Sheshgiri, F. Gustafsson, J. Sheedy, V. Rao, H. J. Ross, and D. H. Delgado, "Everolimus but not mycophenolate mofetil therapy is associated with soluble HLA-G expression in heart transplant patients," Journal of Heart and Lung Transplantation, vol. 28, no. 11, pp. 1193-1197, 2009.

[180] R. Bahri, A. Naji, C. Menier et al., "Dendritic cells secrete the immunosuppressive HLA-G molecule upon CTLA4-Ig treatment: implication in human renal transplant acceptance," Journal of Immunology, vol. 183, no. 11, pp. 7054-7062, 2009.

[181] G. Stallone, P. Pontrelli, B. Infante et al., "Rapamycin induces ILT3ILT4 dendritic cells promoting a new immunoregulatory pathway," Kidney International, vol. 85, no. 4, pp. 888-897, 2014.

[182] B. Fedoric and R. Krishnan, "Rapamycin downregulates the inhibitory receptors ILT2, ILT3, ILT4 on human dendritic cells and yet induces T cell hyporesponsiveness independent of FoxP3 induction," Immunology Letters, vol. 120, no. 1-2, pp. 49-56, 2008.

[183] J. LeMaoult, M. Daouya, J. Wu, M. Loustau, A. Horuzsko, and E. D. Carosella, "Synthetic HLA-G proteins for therapeutic use in transplantation," FASEB Journal, vol. 27, no. 9, pp. 3643-3651, 2013.

[184] M. F. Pittenger, A. M. Mackay, S. C. Beck et al., "Multilineage potential of adult human mesenchymal stem cells," Science, vol. 284, no. 5411, pp. 143-147, 1999.

[185] M. Mathieu, J. Bartunek, B. El Oumeiri et al., "Cell therapy with autologous bone marrow mononuclear stem cells is associated with superior cardiac recovery compared with use of nonmodified mesenchymal stem cells in a canine model of chronic myocardial infarction," Journal of Thoracic and Cardiovascular Surgery, vol. 138, no. 3, pp. 646-653, 2009.

[186] A. Naji, N. Rouas-Freiss, A. Durrbach, E. D. Carosella, L. Sensebe, and F. Deschaseaux, "Concise review: combining human leukocyte antigen G and mesenchymal stem cells for immunosuppressant biotherapy," Stem Cells, vol. 31, no. 11, pp. 2296-2303, 2013.

[187] M. Shi, Z.-W. Liu, and F.-S. Wang, "Immunomodulatory properties and therapeutic application of mesenchymal stem cells," Clinical & Experimental Immunology, vol. 164, no. 1, pp. 1-8, 2011.

[188] Z. Selmani, A. Naji, I. Zidi et al., "Human leukocyte antigenG5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+ CD25highFOXP3+ regulatory T cells," Stem Cells, vol. 26, no. 1, pp. 212-222, 2008.

[189] K. Le Blanc, I. Rasmusson, B. Sundberg et al., "Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells," The Lancet, vol. 363, no. 9419, pp. 1439-1441, 2004.

[190] F. Baron and R. Storb, "Mesenchymal stromal cells: a new tool against graft-versus-host disease?" Biology of Blood and Marrow Transplantation, vol. 18, no. 6, pp. 822-840, 2012.

[191] B. Zhang, Y. Yin, R. C. Lai, S. S. Tan, A. B. Choo, and S. K. Lim, "Mesenchymal stem cells secrete immunologically active exosomes," Stem Cells and Development, vol. 23, no. 11, pp. 1233-1244, 2014.

[192] A. V. Vlassov, S. Magdaleno, R. Setterquist, and R. Conrad, "Exosomes: current knowledge of their composition, biological functions, and diagnostic and therapeutic potentials," Biochimica etBiophysica Acta, vol. 1820, no. 7, pp. 940-948, 2012.

[193] L. Kordelas, V. Rebmann, A. K. Ludwig et al., "MSC-derived exosomes: a novel tool to treat therapy-refractory graft-versus-host disease," Leukemia, 2014.

Vera Rebmann, (1) Fabiola da Silva Nardi, (1,2) Bettina Wagner, (1) and Peter A. Horn (1)

(1) Institute for Transfusion Medicine, University Hospital Essen, Virchowstrafie 179, 45147 Essen, Germany

(2) CAPES Foundation, Ministry of Education of Brazil, 70.040-020 Brasilia, DF, Brazil

Correspondence should be addressed to Vera Rebmann; vera.rebmann@uk-essen.de

Received 14 February 2014; Revised 7 May 2014; Accepted 21 May 2014; Published 21 July 2014

Academic Editor: Marcel Tilanus
COPYRIGHT 2014 Hindawi Limited
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2014 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Research Article
Author:Rebmann, Vera; Nardi, Fabiola da Silva; Wagner, Bettina; Horn, Peter A.
Publication:Journal of Immunology Research
Article Type:Report
Date:Jan 1, 2014
Words:13865
Previous Article:Palladium nanoparticles induce disturbances in cell cycle entry and progression of peripheral blood mononuclear cells: paramount role of ions.
Next Article:A micropolymorphism altering the residue triad 97/114/156 determines the relative levels of tapasin independence and distinct peptide profiles for...
Topics:

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters